JonesResearch analyst Catherine Novack initiated coverage of CalciMedica with a Buy rating and $22 price target. CalciMedica is a clinical-stage biotech focused on inhibition of calcium release-activated calcium channels, the analyst tells investors in a research note. In acute pancreatitis, the firm estimates 20% peak market penetration, translating to $370M in peak sales worldwide. “With multiple shots on goal” in severe inflammatory diseases, the firm is bullish on the shares over the next 12-18 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CALC: